Inhibition of signaling downstream of beta-2 adrenoceptor by propranolol in prostate cancer cells.
PKA
beta-2 adrenoreceptors
epinephrine
propranolol
prostate cancer
stress
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
revised:
07
06
2022
received:
18
08
2021
accepted:
04
07
2022
pubmed:
15
11
2022
medline:
11
1
2023
entrez:
14
11
2022
Statut:
ppublish
Résumé
There is accumulating evidence that propranolol, an antagonist of beta-1 and beta-2 adrenoreceptors, extends survival of patients with prostate cancer; yet it is not known whether propranolol inhibits beta-adrenergic signaling in prostate cancer cells, or systemic effects of propranolol play the leading role in slowing down cancer progression. Recently initiated clinical studies offer a possibility to test whether administration of propranolol inhibits signaling pathways in prostate tumors, however, there is limited information on the dynamics of signaling pathways activated downstream of beta-2 adrenoreceptors in prostate cancer cells and on the inactivation of these pathways upon propranolol administration. Western blot analysis was used to test the effects of epinephrine and propranolol on activation of protein kinase (PKA) signaling in mouse prostates and PKA, extracellular signal-regulated kinase (ERK), and protein kinase B/AKT (AKT) signaling in prostate cancer cell lines. In prostate cancer cell lines epinephrine induced robust phosphorylation of PKA substrates pS133CREB and pS157VASP that was evident 2 min after treatments and lasted for 3-6 h. Epinephrine induced phosphorylation of AKT in PTEN-positive 22Rv1 cells, whereas changes of constitutive AKT phosphorylation were minimal in PTEN-negative PC3, C42, and LNCaP cells. A modest short-term increase of pERK in response to epinephrine was observed in all tested cell lines. Incubation of prostate cancer cells with 10-fold molar excess of propranolol for 30 min inhibited all downstream pathways activated by epinephrine. Subjecting mice to immobilization stress induced phosphorylation of S133CREB, whereas injection of propranolol at 1.5 mg/kg prevented the stress-induced phosphorylation. The analysis of pS133CREB and pS157VASP allows measuring activation of PKA signaling downstream of beta-2 adrenoreceptors. Presented results on the ratio of propranolol/epinephrine and the time needed to inhibit signaling downstream of beta-2 adrenoreceptors will help to design clinical studies that examine the effects of propranolol on prostate tumors.
Sections du résumé
BACKGROUND
There is accumulating evidence that propranolol, an antagonist of beta-1 and beta-2 adrenoreceptors, extends survival of patients with prostate cancer; yet it is not known whether propranolol inhibits beta-adrenergic signaling in prostate cancer cells, or systemic effects of propranolol play the leading role in slowing down cancer progression. Recently initiated clinical studies offer a possibility to test whether administration of propranolol inhibits signaling pathways in prostate tumors, however, there is limited information on the dynamics of signaling pathways activated downstream of beta-2 adrenoreceptors in prostate cancer cells and on the inactivation of these pathways upon propranolol administration.
METHODS
Western blot analysis was used to test the effects of epinephrine and propranolol on activation of protein kinase (PKA) signaling in mouse prostates and PKA, extracellular signal-regulated kinase (ERK), and protein kinase B/AKT (AKT) signaling in prostate cancer cell lines.
RESULTS
In prostate cancer cell lines epinephrine induced robust phosphorylation of PKA substrates pS133CREB and pS157VASP that was evident 2 min after treatments and lasted for 3-6 h. Epinephrine induced phosphorylation of AKT in PTEN-positive 22Rv1 cells, whereas changes of constitutive AKT phosphorylation were minimal in PTEN-negative PC3, C42, and LNCaP cells. A modest short-term increase of pERK in response to epinephrine was observed in all tested cell lines. Incubation of prostate cancer cells with 10-fold molar excess of propranolol for 30 min inhibited all downstream pathways activated by epinephrine. Subjecting mice to immobilization stress induced phosphorylation of S133CREB, whereas injection of propranolol at 1.5 mg/kg prevented the stress-induced phosphorylation.
CONCLUSIONS
The analysis of pS133CREB and pS157VASP allows measuring activation of PKA signaling downstream of beta-2 adrenoreceptors. Presented results on the ratio of propranolol/epinephrine and the time needed to inhibit signaling downstream of beta-2 adrenoreceptors will help to design clinical studies that examine the effects of propranolol on prostate tumors.
Identifiants
pubmed: 36373761
doi: 10.1002/pros.24455
pmc: PMC10100053
doi:
Substances chimiques
Propranolol
9Y8NXQ24VQ
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Epinephrine
YKH834O4BH
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
237-245Subventions
Organisme : NCI NIH HHS
ID : P30 CA012197
Pays : United States
Informations de copyright
© 2022 The Authors. The Prostate published by Wiley Periodicals LLC.
Références
Science. 2013 Jul 12;341(6142):1236361
pubmed: 23846904
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18862-7
pubmed: 24190998
Sci Signal. 2012 Dec 04;5(253):ra89
pubmed: 23211529
Biochem Pharmacol. 2003 May 1;65(9):1489-94
pubmed: 12732361
Cancers (Basel). 2019 Mar 13;11(3):
pubmed: 30871232
Science. 2005 Apr 22;308(5721):512-7
pubmed: 15845844
Prostate. 2004 Jan 1;58(1):50-6
pubmed: 14673952
Biochem Pharmacol. 2007 Mar 15;73(6):814-23
pubmed: 17196553
Int Urol Nephrol. 1996;28(1):61-6
pubmed: 8738621
Br J Clin Pharmacol. 2011 Jul;72(1):157-61
pubmed: 21453301
Prostate Suppl. 1989;2:5-16
pubmed: 2619992
Cancer Epidemiol. 2014 Jun;38(3):279-85
pubmed: 24786858
J Biol Chem. 2007 May 11;282(19):14094-100
pubmed: 17353197
Kurume Med J. 1990;37(1):1-8
pubmed: 1976852
Invest Urol. 1980 Jan;17(4):293-7
pubmed: 7351361
Mol Endocrinol. 2001 Apr;15(4):553-64
pubmed: 11266507
Nucleic Acids Res. 2003 Feb 15;31(4):e15
pubmed: 12582260
Oncogene. 2017 Mar;36(11):1525-1536
pubmed: 27641328
Prostate Suppl. 1998;8:2-13
pubmed: 9690657
J Clin Invest. 2013 Feb;123(2):874-86
pubmed: 23348742
Medicine (Baltimore). 2015 Jul;94(27):e1097
pubmed: 26166098
J Urol. 1990 Nov;144(5):1263-6
pubmed: 1700147
Mol Cancer Res. 2017 Dec;15(12):1644-1655
pubmed: 28814453
Front Oncol. 2015 Jan 12;4:375
pubmed: 25629002
Circ Res. 2000 Dec 8;87(12):1172-9
pubmed: 11110775
Diabetologia. 2007 Jan;50(1):158-67
pubmed: 17119919
Eur Urol. 2014 Mar;65(3):635-41
pubmed: 23351721
Prostate. 2023 Feb;83(3):237-245
pubmed: 36373761
EMBO J. 2011 Jun 03;30(13):2557-68
pubmed: 21642958
Science. 2017 Oct 20;358(6361):321-326
pubmed: 29051371
PLoS One. 2013 Sep 05;8(9):e74561
pubmed: 24040284
Pharmacol Ther. 2018 Nov;191:135-147
pubmed: 29909235
Cell Death Dis. 2017 Jun 1;8(6):e2844
pubmed: 28569785
Prostate. 2020 Nov;80(15):1328-1340
pubmed: 32894788
Cell Tissue Res. 1995 Sep;281(3):533-42
pubmed: 7553772
Oncogene. 2018 May;37(22):2953-2966
pubmed: 29515233
J Biol Chem. 2006 Jul 28;281(30):20891-20901
pubmed: 16728406
Clin Rev Allergy Immunol. 1996 Spring;14(1):37-45
pubmed: 8866170